A process for synthesizing and separating secretory IgA from a mixture of IgA monmer and IgA dimer is provided. The process includes covalently binding affinity tagged or epitope tagged recombinant secretory component to the IgA dimer in the mixture and binding the affinity tagged or an epitope tagged secretory IgA to immobilized moieties on the solid phase support resin to which the affinity tag or epitope tag binds and then eluting the affinity tagged or an epitope tagged secretory IgA with release buffer. A process for synthesizing and separating secretory IgM from a mixture of IgM and other plasma proteins is also provided. The process includes covalently binding affinity tagged or an epitope tagged recombinant secretory component to the IgM in the mixture and binding the affinity tagged or an epitope tagged secretory IgM to immobilized moieties on the solid phase support resin and then eluting the peptide tagged secretory IgM with a release buffer.

The invention discloses a method for the detection of sialate glycosyl casein glycomacropeptide by boronate affinity column enrichment-liquid chromatography-tandem mass spectrometry using phenylboric acid modified mesoporous silica as packing material, which belongs to the field of food analysis and detection. The method includes the following steps: (1) sample preparation; (2) enrichment and purification of boronate affinity column; (3) liquid chromatography-tandem mass spectrometry detection. The invention makes use of the affinity property of phenylboric acid to the special sugar group sialic acid on the serine and threonine residues in casein glycogiant peptide, regulates the adsorption and elution of casein glycogiant peptide with sialic acid group by changing pH. Combined with the high sensitivity and accuracy of liquid chromatography tandem mass spectrometry, it can be used for qualitative and quantitative analysis of casein glycomacropeptide with sialate glycol-group in phenylketonuria special medical formulations with complex matrix.

The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods are capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.

A fully-automatic protein purification system device includes a chromatography unit, a first drive unit, a connecting pipeline, a locating unit, a second drive unit, a first container, a second container, a first valve, a second valve, and a control unit. The fully-automatic protein purification system device can fully automate the protein chromatography purification with a simple device structure and a low cost, has low requirements for the quality of a sample solution, will not cause blockage of a pipeline, has a wide application range, can greatly improve the automation of protein chromatography purification in the biology field, and can reduce the manual investment.

Provided are methods and columns employing a solid support comprising silica and silicon carbide for the isolation and purification of nucleic acids, and in particular, the isolation and purification of both high and low molecular weight RNA.

Disclosed is a method for filtering a fibrinogen composition, comprising the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and/or thawing step.

The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibers which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid DNA. The invention further provides for the use of the chromatographic medium in a simulated moving bed system.

The present invention provides a method for purifying Chondroitinase ABC (ChABC). The present method includes using a heparin-immobilized affinity chromatography column, and through chromatography method obtaining a purified ChABC from a matrix containing the ChABC. The present method is capable of obtaining ChABC in high purity with the advantages of simplicity in preparation and high yield.

The present invention refers to new species of an ion exchange adsorber which is suitable for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies. The invention especially refers to a process for purifying biological samples by separating biomolecules of interest and impurities, comprising steps of contacting a sample with said chromatography media consisting of fibers, said fibers having imparted thereon functionality enabling ion exchange chromatography and/or hydrophobic interaction.

A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; and recovering the cleansed product. A method of preparing a universal blood product comprising obtaining a blood product; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; wherein at least one of the hydroxyapatite, carbonaceous material and support matrix is functionalized.